Savara Inc (NASDAQ:SVRA) Stock Holdings Increased by Nantahala Capital Management LLC

Nantahala Capital Management LLC grew its position in Savara Inc (NASDAQ:SVRA - Free Report) by 45.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,525,259 shares of the company's stock after acquiring an additional 2,344,308 shares during the quarter. Savara makes up approximately 1.0% of Nantahala Capital Management LLC's holdings, making the stock its 13th largest position. Nantahala Capital Management LLC owned 4.38% of Savara worth $23,103,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Barclays PLC raised its holdings in shares of Savara by 217.5% during the third quarter. Barclays PLC now owns 231,005 shares of the company's stock worth $979,000 after purchasing an additional 158,244 shares during the period. Geode Capital Management LLC lifted its holdings in Savara by 10.8% in the third quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company's stock worth $11,564,000 after acquiring an additional 264,825 shares during the last quarter. Virtu Financial LLC acquired a new position in Savara in the third quarter valued at approximately $67,000. JPMorgan Chase & Co. grew its holdings in shares of Savara by 23.9% during the third quarter. JPMorgan Chase & Co. now owns 69,490 shares of the company's stock valued at $295,000 after purchasing an additional 13,420 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Savara by 14.0% during the 4th quarter. SG Americas Securities LLC now owns 51,589 shares of the company's stock worth $158,000 after purchasing an additional 6,330 shares during the period. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Stock Performance

Shares of NASDAQ:SVRA traded up $0.14 on Friday, hitting $3.40. The company's stock had a trading volume of 706,717 shares, compared to its average volume of 1,297,425. Savara Inc has a 12 month low of $2.26 and a 12 month high of $5.31. The stock's 50-day moving average is $2.82 and its two-hundred day moving average is $3.06. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The company has a market capitalization of $586.95 million, a price-to-earnings ratio of -7.91 and a beta of 0.52.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). The firm had revenue of $0.27 million for the quarter. On average, equities research analysts forecast that Savara Inc will post -0.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $6.00 target price on shares of Savara in a research report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.83.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.